drugset / Trial / NCT05011669

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

NCT05011669

Phase 4 Completed 200 enrolled Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia

Timeline

Start
2021-08-16
Primary completion
2023-04-16
Completion
2023-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg Oral
Subject Lurasidone Small molecule 80 mg Oral

Indications